These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 6131212)
1. Effect of acute aluminium overload on calcium and parathyroid-hormone metabolism. Cannata JB; Briggs JD; Junor BJ; Fell GS; Beastall G Lancet; 1983 Mar; 1(8323):501-3. PubMed ID: 6131212 [TBL] [Abstract][Full Text] [Related]
2. Hypercalcaemia, hypermagnesaemia, hyperphosphataemia and hyperaluminaemia in CAPD: improvement in serum biochemistry by reduction in dialysate calcium and magnesium concentrations. Hutchison AJ; Were AJ; Boulton HF; Mawer EB; Laing I; Gokal R Nephron; 1996; 72(1):52-8. PubMed ID: 8903861 [TBL] [Abstract][Full Text] [Related]
3. Low calcium peritoneal dialysis solution. Effects on calcium metabolism and bone disease in CAPD patients. Carozzi S; Nasini MG; Schelotto C; Caviglia PM; Santoni O; Pietrucci A ASAIO J; 1992; 38(3):M593-5. PubMed ID: 1457929 [TBL] [Abstract][Full Text] [Related]
4. Low calcium (1.25 mmol/L) dialysate can normalize relative hypoparathyroidism in CAPD patients with low bone turnover. Shigematsu T; Kawaguchi Y; Kubo H; Nakayama M; Kato N; Yamamoto H; Osaka N; Hayakawa H; Ogawa A; Sakai O Adv Perit Dial; 1996; 12():250-6. PubMed ID: 8865914 [TBL] [Abstract][Full Text] [Related]
5. Effect of aluminium hydroxide on serum ionised calcium, immunoreactive parathyroid hormone, and aluminium in chronic renal failure. Biswas CK; Arze RS; Ramos JM; Ward MK; Dewar JH; Kerr DN; Kenward DH Br Med J (Clin Res Ed); 1982 Mar; 284(6318):776-8. PubMed ID: 6802224 [TBL] [Abstract][Full Text] [Related]
6. Relationship between the serum parathyroid hormone and magnesium levels in continuous ambulatory peritoneal dialysis (CAPD) patients using low-magnesium peritoneal dialysate. Cho MS; Lee KS; Lee YK; Ma SK; Ko JH; Kim SW; Kim NH; Choi KC Korean J Intern Med; 2002 Jun; 17(2):114-21. PubMed ID: 12164088 [TBL] [Abstract][Full Text] [Related]
7. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone. Bro S; Brandi L; Olgaard K Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216 [TBL] [Abstract][Full Text] [Related]
8. Low-calcium dialysis fluid and oral calcium carbonate in CAPD. A method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcaemia. Hutchison AJ; Freemont AJ; Boulton HF; Gokal R Nephrol Dial Transplant; 1992; 7(12):1219-25. PubMed ID: 1337163 [TBL] [Abstract][Full Text] [Related]
9. The influence of aluminium on parathyroid hormone levels in haemodialysis patients. Cannata JB; Briggs JD; Junor BJ; Beastall G; Fell GS Proc Eur Dial Transplant Assoc; 1983; 19():244-7. PubMed ID: 6878239 [TBL] [Abstract][Full Text] [Related]
11. Reversibility of parathyroid gland suppression in CAPD patients with low i-PTH levels. Montenegro J; Saracho R; González O; Moina I; Martínez I Clin Nephrol; 1997 Dec; 48(6):359-63. PubMed ID: 9438094 [TBL] [Abstract][Full Text] [Related]
12. Level-dependent inhibitory effect of hyperaluminaemia on parathyroid hormone secretion in patients with end-stage renal failure. Fernández E; Amoedo ML; Montoliu J Eur J Med; 1992 Dec; 1(8):482-4. PubMed ID: 1341207 [TBL] [Abstract][Full Text] [Related]
13. Parathyroid hormone during maintenance dialysis: influence of low calcium dialysate, plasma albumin and age. Heaf JG; Løkkegård H J Nephrol; 1998; 11(4):203-10. PubMed ID: 9702872 [TBL] [Abstract][Full Text] [Related]
14. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity. McCarthy JT; Milliner DS; Johnson WJ Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295 [TBL] [Abstract][Full Text] [Related]
15. Calcium concentration in the CAPD dialysate: what is optimal and is there a need to individualize? Bro S; Brandi L; Daugaard H; Olgaard K Perit Dial Int; 1997; 17(6):554-9. PubMed ID: 9655154 [TBL] [Abstract][Full Text] [Related]
16. Effect of aluminium on the development of hyperparathyroidism and bone disease in the azotaemic rat. Felsenfeld AJ; Machado L; Bover J; Trinidad P; Rodriguez M Nephrol Dial Transplant; 1993; 8(4):325-34. PubMed ID: 8390007 [TBL] [Abstract][Full Text] [Related]
17. The requirement of low calcium dialysate in patients on continuous ambulatory peritoneal dialysis receiving calcium carbonate as a phosphate binder. Cheng IK; Lu HB; Chan CY; Cheng SW; Robinson JD; Tam SC; Lo WK; Cheung WC Clin Nephrol; 1993 Aug; 40(2):100-5. PubMed ID: 8222365 [TBL] [Abstract][Full Text] [Related]
18. A randomized trial comparing 1.25 mmol/l calcium dialysate to 1.75 mmol/l calcium dialysate in CAPD patients. Johnson DW; Rigby RJ; McIntyre HD; Brown A; Freeman J Nephrol Dial Transplant; 1996 Jan; 11(1):88-93. PubMed ID: 8649658 [TBL] [Abstract][Full Text] [Related]
19. Reversal of adynamic bone disease by lowering of dialysate calcium. Haris A; Sherrard DJ; Hercz G Kidney Int; 2006 Sep; 70(5):931-7. PubMed ID: 16837920 [TBL] [Abstract][Full Text] [Related]
20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]